Endoglin and Systemic Sclerosis: A PRISMA-driven systematic review

Silvia Grignaschi1,2, Anna Sbalchiero3, Giuseppe Spinozzi4

  • 1Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy.

Frontiers in Medicine
|September 5, 2022
PubMed
Abstract

Insights

Systemic Sclerosis (SSc) involves altered Endoglin (ENG) expression and soluble levels, impacting Transforming Growth Factor β pathways. This review highlights ENG's crucial role in SSc pathogenesis and progression.

Area of Science:

  • Autoimmune diseases
  • Molecular biology
  • Clinical research

Background:

  • Systemic Sclerosis (SSc) is a rare autoimmune disease with poorly understood pathogenesis.
  • The Transforming Growth Factor β (TGFβ) superfamily is implicated, with Endoglin (ENG) suggested as a key type III receptor.
  • This systematic review aims to consolidate clinical and molecular data on ENG in SSc to guide future research.

Approach:

  • Systematic review following PRISMA guidelines, searching MEDLINE, Web of Science, and Embase up to November 2, 2021.
  • Inclusion criteria focused on the ENG-SSc relationship, excluding studies solely on ENG as a biomarker or review articles.
  • Records were categorized into clinical and molecular studies for detailed analysis.

Key Points:

  • Analysis of 25 original papers and 10 conference abstracts revealed altered ENG expression in SSc-affected cells.
  • Clinical studies indicated correlations between SSc phenotypes and dysregulated soluble ENG concentrations.
  • Molecular studies focused on ENG expression across various cell types in SSc.

Conclusions:

  • Endoglin (ENG) plays a pivotal role in activating TGFβ-stimulated pathways critical for SSc pathogenesis.
  • Altered ENG expression and soluble levels are linked to SSc development and progression.
  • Further research into ENG's function in SSc is warranted.